FOR IMMEDIATE PRESS RELEASE: June 16, 2011
In a just released AEI Health Policy Outlook, AEI scholar Scott Gottlieb, M.D. argues that adding a new mandatory "comparative effectiveness" test to the approval process for new drugs in the reauthorization of the Food and Drug Administration (FDA) Prescription Drug User Fee Act constitutes a needless waste of time and money.
Among the key points:
- Consumer groups are pushing to add a step to the FDA drug approval process: "comparator" trials, which test a new drug against the current standard treatment.
- But these trials are already being conducted where it really matters. A new FDA approval requirement would unnecessarily slow down the approval process for all other drugs.
- Achieving the goal consumer groups want--safer and more cost-effective drugs--requires innovation in clinical trial design, not a congressional mandate.